under preclinical or clinical development. 2 The major goal of HAART is the stable suppression of viral replication, but factors such as suboptimal adherence to therapy, drug-drug interactions, and side effects can compromise the efficacy of an antiretroviral regimen, eventually leading to the development of drug resistance. 3 Current guidelines indeed recommend the monitoring of drug resistance both at HIV diagnosis and at treatment failure, as the determination of the resistance profile is a necessary step to guide treatment decisions. 4 Due to extensive accumulation of data correlating HIV mutations with changes of drug susceptibility in vitro and in vivo, genotypic testing is the recommended approach to monitor for HIV drug resistance in clinical practice. The HIV genomic regions of interest are sequenced and susceptibility to the different drugs is inferred based on updated algorithms translating the mutational pattern into clinical activity. 5 Since genotype interpretation algorithms by definition consider only well characterized resistance mutations, complex and/or unusual mutational patterns can be occasionally difficult to translate into clinically useful information. As opposed to genotypic testing, phenotypic assays allow direct measurement of drug susceptibility of any viral strain, independently from the complexity of the mutational pattern, by evaluating the replication of the viral strain in the presence of serial dilutions of drugs in cell culture. 6 Unfortunately, phenotypic assay are not amenable to routine diagnostics due to the higher cost and turnaround time compared to genotypic assays, the need of higher level expertise and biosafety level 3 facilities when replication-competent virus must be handled.
However, phenotypic assays remain essential in the determination of the antiviral activity and definition of the resistance profile of investigational drugs. Two highly standardized large-scale commercial phenotypic services have been used to characterize most of the currently licensed antiretrovirals during preclinical development and/or clinical trials. 7, 8 Other small-scale phenotypic assays have been reported mainly in the academia [9] [10] [11] [12] and it is important to establish how these compare to the two reference commercial assays. We have developed a recombinant virus assay based on the production of chimeric viruses through homologous recombination in eukaryotic cells by cotransfecting the PCR fragment of interest and the corresponding member of a family of deleted pNL4-3-derived vectors. The PCR insert may derive from a clinical sample or from a laboratory adapted virus or clone. In this paper, we report the reproducibility and the accuracy of this system using clones with resistance mutations already characterized with the commercially available Phenosense assay (Monogram Biosciences, South San Francisco, CA, USA). 
| MATERIALS AND METHODS

| Overview of the method and performance analysis
The assay separately considers the gag-protease (PR), reverse Figure 1 shows the steps of the whole procedure.
The interassay reproducibility of the system was evaluated by trip- 
| Cell lines and plasmids
293FT cells (Thermo Fisher Scientific, Waltham, MA, USA) were cultured in DMEM high glucose with L-glutamine, supplemented with 10% fetal bovine serum, 100 U/mL penicillin, 100 μg/mL streptomycin, and 300 μg/mL geneticin. TZM-bl cells were cultured in DMEM supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 μg/mL streptomycin. MT-2 cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum, 2 mmol/L glutamine, 100 U/mL penicillin, and 100 μg/mL strepto- 
| Antiviral drugs
The PIs atazanavir (ATV) and darunavir (DRV), the NRTIs tenofovir disoproxil fumarate (TDF) and abacavir (ABC), the NNRTIs efavirenz (EFV) and rilpivirine (RPV), and the INI raltegravir (RAL) were obtained from the AIDS Reagent Program.
| Generation of vector and insert for production of chimeric virus through homologous recombination
A family of pNL4-3-based deleted vectors was obtained through inverse PCR following cloning of a pNL4-3 fragment comprising the region to be deleted into the shuttle vector pCR2.1 (Thermo Fisher Scientific). Inverse PCR was run using Expand Long Range DNA polymerase (Roche Diagnostics, Basel, Switzerland) as suggested by the manufacturer, with primers bearing a unique SacII restriction site at the 5′ end to allow circularization of the deleted amplified product through SacII digestion and T4 ligation (see Table S1 ). Following confirmation of the desired deletion in the shuttle vector, the deleted region was moved back to the original pNL4-3 backbone to obtain the deleted vector of interest.
Target-specific PCR protocols were set up to create a Gag-PR, RT-RNaseH, or IN PCR fragment overlapping by about 100-200 bp at the 5′ and 3′ end of the corresponding linearized deleted vector.
The plasmids carrying the infectious clones with drug resistance mutations were used as templates to generate the Gag-PR, RT-RNaseH, or IN insert regions through PCR. Since the assay could also be used with clinical samples requiring maximum sensitivity, nested amplification primers (Eurofins Genomics, Ebersberg, Germany) ( Table 2) were designed to match to highly conserved regions, based on the 
| Transfection, expansion, and titration of recombinant viruses
The day before transfection, 1.5 million 293FT cells were seeded in a T25 flask in a total volume of 8 mL of growth medium. For the production of recombinant viruses to be used in the accuracy experiments, four replicates of the inner PCR product were coprecipitated with 10 μg of the corresponding SacII-linearized NL4-3 deleted
T A B L E 2 Primers used for the amplification of target HIV-1 regions and relative thermal cycler protocols
Primer ID Sequence (5′-3′) The solution was incubated at room temperature for 30 minutes, then added to the cells in the presence of 3 mL of fresh medium.
Following overnight incubation, the medium was replaced with 8 mL of DMEM without geneticin. After 48 hours the medium was centrifuged at 300 g for 10 minutes and 3 mL of supernatant were F I G U R E 2 Dose-response curves for calculating the inter-assay reproducibility of drug susceptibility testing, expressed as fold change (FC) with respect to the wildtype reference virus. Numbers indicate the respective molecular clone as indicated in Table 1 . R1, R2, and R3 indicate the replicate experiment done. ABC, abacavir; ATV, atazanavir, DRV, darunavir; EFV, efavirenz; RAL, raltegravir; RPV, rilpivirine; TDF, tenofovir disoproxil fumarate 
| Estimation of susceptibility to anti-HIV-1 drugs through MonoCycle and BiCycle assays
The MonoCycle assay was developed to measure susceptibility to 
| Interassay reproducibility of drug susceptibility testing
The interassay reproducibility of drug susceptibility testing was evaluated through the determination of the IC 50 of two most commonly used NRTIs, NNRTIs, and PIs, and one representative INI. The IC 50 was calculated using one virus for each class of drugs, selected among the infectious clones with moderate or high-level resistance as determined by the reference Phenosense assay (Table 3 and Figure 2 ).
Each virus-drug pair was tested in three independent assays and the 
| Assay accuracy with recombinant viral strains
To evaluate the accuracy of the whole assay starting from generation of the PCR product, recombinant viruses were created through homologous recombination between the deleted vectors and the corresponding PCR fragments amplified from the drug-resistant clones.
Three recombinant viruses carrying PI, NRTI, or NNRTI resistance mutations, and two carrying INI resistance mutations were tested in a single run with the same drugs used in the interassay reproducibility testing (Table 4) . FC values calculated in this experiment were again very close to those reported with the Phenosense assay, with mean±SD Phenosense to in-house ratio of 1.14±0.33 and no cases differing by more than twofold, implying that the additional steps of amplification and recombination did not impact the accuracy of 
| DISCUSSION
HIV drug resistance has been a major issue since the introduction of antiretroviral therapy. Once drug resistance mutations have been well defined, genotypic assays can effectively assist treatment decisions in most clinical settings. 3 However, phenotypic methods remain instrumental when the resistance profile must be characterized for investigational compounds or better clarified for newly introduced drugs. Indeed, development of any new drug must take into account its activity against circulating drug-resistant strains.
The phenotypic assay described here is based on the production of recombinant viruses between any derived PCR fragment and a spe- 
